Rhabdomyosarcoma in low- and middle-income countries: A report from the Asociacion de Hemato-oncología Pediatrica de Centro América (AHOPCA).
Claudia GarridoTomás LetonaSusana GodoyFederico AntillónPatricia ValverdeSandra Luna-FinemanCarlos Rodriguez GalindoSoad FuentesIngrid ArambuPatricia CalderónRoberta OrtizMargarita MonteroJessica BlancoMaria Grazia ValsecchiAndrea C FerrariPublished in: Pediatric blood & cancer (2022)
This report describes the results of an observational study dedicated to rhabdomyosarcoma developed by the Asociación de Hemato-oncología Pediatrica de Centro América (AHOPCA) between 2001 and 2018. Overall, 337 previously untreated patients < 18 years old were included in the analysis; 58% had unresected disease, and 19% were metastatic at diagnosis. With a median follow-up of 6.6 years, five-year event-free and overall survival rates were 30% and 33%, respectively. Local progression/relapse was the main cause of treatment failure.